VYNE Therapeutics (VYNE) Insider Trading & Ownership $0.36 -0.02 (-5.36%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$0.35 0.00 (-0.81%) As of 08/8/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VYNE Therapeutics (NASDAQ:VYNE) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.80%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$43.80KNumber OfInsiders Selling(Last 12 Months)0 Get VYNE Insider Trade Alerts Want to know when executives and insiders are buying or selling VYNE Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address VYNE Insider Buying and Selling by Quarter VYNE Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails1/15/2025Patrick G LeporeDirectorBuy15,000$2.92$43,800.00 (Data available from 1/1/2013 forward) VYNE Insider Trading Activity - Frequently Asked Questions Who is on VYNE Therapeutics' Insider Roster? The list of insiders at VYNE Therapeutics includes Mutya Harsch, and Patrick G Lepore. Learn more on insiders at VYNE. What percentage of VYNE Therapeutics stock is owned by insiders? 4.80% of VYNE Therapeutics stock is owned by insiders. Learn more on VYNE's insider holdings. Which VYNE Therapeutics insiders have been buying company stock? The following insider purchased VYNE shares in the last 24 months: Patrick G Lepore ($94,630.00). How much insider buying is happening at VYNE Therapeutics? Insiders have purchased a total of 28,000 VYNE shares in the last 24 months for a total of $94,630.00 bought. VYNE Therapeutics Key ExecutivesMr. David T. Domzalski (Age 57)CEO, President & Director Compensation: $1.61MDr. Iain A. Stuart Ph.D. (Age 51)Chief Scientific Officer Compensation: $856.82kMs. Mutya Harsch J.D. (Age 49)General Counsel, Chief Legal Officer & Company Secretary Compensation: $817.97kMr. Tyler Zeronda (Age 37)CFO & Treasurer Dr. Darrell S. Rigel FAAD (Age 73)M.D., Consultant Compensation: $40.2k More Insider Trading Tools from MarketBeat Related Companies ATNF Insider Trading ADAP Insider Trading RVPH Insider Trading CVKD Insider Trading MBRX Insider Trading FNCH Insider Trading RLMD Insider Trading CMMB Insider Trading BCAB Insider Trading PASG Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Strategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months This page (NASDAQ:VYNE) was last updated on 8/10/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
